AZN vs ZTS: fair value comparison
AstraZeneca PLC and Zoetis Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ZTS currently sits closer to the top of our discount ranking. AZN carries the stronger quality grade. AZN carries the stronger momentum grade.
| AZN | ZTS | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $156.93 | $77.34 |
| 12-month range | $156.06–$202.39 | $77.10–$152.88 |
| Sector rank | #6 of 113 Healthcare | #5 of 113 Healthcare |
| Quality grade | B | C |
| Momentum grade | A | B |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AZN fair value analysis · ZTS fair value analysis